216 related articles for article (PubMed ID: 26014522)
1. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production.
Walther J; Godawat R; Hwang C; Abe Y; Sinclair A; Konstantinov K
J Biotechnol; 2015 Nov; 213():3-12. PubMed ID: 26014522
[TBL] [Abstract][Full Text] [Related]
2. Modeling the Downstream Processing of Monoclonal Antibodies Reveals Cost Advantages for Continuous Methods for a Broad Range of Manufacturing Scales.
Hummel J; Pagkaliwangan M; Gjoka X; Davidovits T; Stock R; Ransohoff T; Gantier R; Schofield M
Biotechnol J; 2019 Feb; 14(2):e1700665. PubMed ID: 29341493
[TBL] [Abstract][Full Text] [Related]
3. A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies.
Xenopoulos A
J Biotechnol; 2015 Nov; 213():42-53. PubMed ID: 25959171
[TBL] [Abstract][Full Text] [Related]
4. Integrated continuous production of recombinant therapeutic proteins.
Warikoo V; Godawat R; Brower K; Jain S; Cummings D; Simons E; Johnson T; Walther J; Yu M; Wright B; McLarty J; Karey KP; Hwang C; Zhou W; Riske F; Konstantinov K
Biotechnol Bioeng; 2012 Dec; 109(12):3018-29. PubMed ID: 22729761
[TBL] [Abstract][Full Text] [Related]
5. Economics and ecology: Modelling of continuous primary recovery and capture scenarios for recombinant antibody production.
Cataldo AL; Burgstaller D; Hribar G; Jungbauer A; Satzer P
J Biotechnol; 2020 Jan; 308():87-95. PubMed ID: 31809781
[TBL] [Abstract][Full Text] [Related]
6. Implementation of Fully Integrated Continuous Antibody Processing: Effects on Productivity and COGm.
Arnold L; Lee K; Rucker-Pezzini J; Lee JH
Biotechnol J; 2019 Feb; 14(2):e1800061. PubMed ID: 29729129
[TBL] [Abstract][Full Text] [Related]
7. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty.
Pollock J; Ho SV; Farid SS
Biotechnol Bioeng; 2013 Jan; 110(1):206-19. PubMed ID: 22806692
[TBL] [Abstract][Full Text] [Related]
8. A modular and multi-functional purification strategy that enables a common framework for manufacturing scale integrated and continuous biomanufacturing.
Pybus LP; Heise C; Nagy T; Heeran C; Dover T; Raven J; Kori J; Burton G; Sakuyama H; Hastings B; Lyons M; Nakai S; Haigh J
Biotechnol Prog; 2024 Mar; ():e3456. PubMed ID: 38494903
[TBL] [Abstract][Full Text] [Related]
9. Continuous Manufacturing of Recombinant Therapeutic Proteins: Upstream and Downstream Technologies.
Patil R; Walther J
Adv Biochem Eng Biotechnol; 2018; 165():277-322. PubMed ID: 28265699
[TBL] [Abstract][Full Text] [Related]
10. Integrated continuous biomanufacturing platform with ATF perfusion and one column chromatography operation for optimum resin utilization and productivity.
Kamga MH; Cattaneo M; Yoon S
Prep Biochem Biotechnol; 2018 May; 48(5):383-390. PubMed ID: 29509101
[TBL] [Abstract][Full Text] [Related]
11. Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.
Xu J; Xu X; Huang C; Angelo J; Oliveira CL; Xu M; Xu X; Temel D; Ding J; Ghose S; Borys MC; Li ZJ
MAbs; 2020 Jan; 12(1):1770669. PubMed ID: 32425110
[TBL] [Abstract][Full Text] [Related]
12. Continuous processing for production of biopharmaceuticals.
Rathore AS; Agarwal H; Sharma AK; Pathak M; Muthukumar S
Prep Biochem Biotechnol; 2015; 45(8):836-49. PubMed ID: 25674930
[TBL] [Abstract][Full Text] [Related]
13. Uncorking the biomanufacturing bottleneck.
Dove A
Nat Biotechnol; 2002 Aug; 20(8):777-9. PubMed ID: 12148000
[No Abstract] [Full Text] [Related]
14. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production.
Nandi S; Kwong AT; Holtz BR; Erwin RL; Marcel S; McDonald KA
MAbs; 2016; 8(8):1456-1466. PubMed ID: 27559626
[TBL] [Abstract][Full Text] [Related]
15. White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium.
Konstantinov KB; Cooney CL
J Pharm Sci; 2015 Mar; 104(3):813-20. PubMed ID: 25417595
[TBL] [Abstract][Full Text] [Related]
16. End-to-end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies.
Mahal H; Branton H; Farid SS
Biotechnol Bioeng; 2021 Sep; 118(9):3468-3485. PubMed ID: 33792918
[TBL] [Abstract][Full Text] [Related]
17. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Srai JS; Badman C; Krumme M; Futran M; Johnston C
J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
[TBL] [Abstract][Full Text] [Related]
18. Reviewing the process intensification landscape through the introduction of a novel, multitiered classification for downstream processing.
Crowley L; Cashen P; Noverraz M; Lobedann M; Nestola P
Biotechnol Bioeng; 2024 Mar; 121(3):877-893. PubMed ID: 38214109
[TBL] [Abstract][Full Text] [Related]
19. Pilot-scale demonstration of an end-to-end integrated and continuous biomanufacturing process.
Coolbaugh MJ; Varner CT; Vetter TA; Davenport EK; Bouchard B; Fiadeiro M; Tugcu N; Walther J; Patil R; Brower K
Biotechnol Bioeng; 2021 Sep; 118(9):3287-3301. PubMed ID: 33410159
[TBL] [Abstract][Full Text] [Related]
20. A new large-scale manufacturing platform for complex biopharmaceuticals.
Vogel JH; Nguyen H; Giovannini R; Ignowski J; Garger S; Salgotra A; Tom J
Biotechnol Bioeng; 2012 Dec; 109(12):3049-58. PubMed ID: 22688835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
